Endocrine Syndromes Flashcards

1
Q

multiple endocrine neoplasia syndromes (MEN) - overview

A

*all 3 are autosomal DOMINANT (50% chance of inheritance)
*MEN1 = menin 1 gene; 3 Ps - Pituitary adenoma, Parathyroid adenoma, Pancreatic neuroendocrine tumors
*MEN2 = RET proto-oncogene; 2 Ps - medullary thyroid carcinoma, Parathyroid adenoma, Pheochromocytoma
*MEN3 = RET proto-oncogene; 1 P - medullary thyroid carcinoma, Pheocromocytoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

MEN1 - associated gene

A

*menin 1 (MEN1) gene
*inheritance = autosomal dominant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

MEN1 - associated tumors

A

*3 P’s:
1. Pituitary adenoma
2. Parathyroid adenoma (hyperparathyroidism)
3. Pancreatic neuroendocrine tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MEN1 - additional manifestations

A

*skin findings: lipomas, angiofibromas, collagenomas
*adrenal tumors
*thyroid tumors
*uterine leiomyomas
*breast cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

MEN1 - clinical diagnosis

A

*a patient presenting with 2 or more MEN1-associated tumors
*recall: MEN1 associated tumors = pituitary adenoma, parathyroid adenoma, and/or pancreatic neuroendocrine tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

MEN1 - familial diagnosis

A

*a patient with 1 MEN1-assocaited tumor and first-degree relative with MEN1
*recall: MEN1 associated tumors = pituitary adenoma, parathyroid adenoma, and/or pancreatic neuroendocrine tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

MEN1 - genetic diagnosis

A

*an individual who has a MEN1 mutation but does not have clinical or biochemical manifestations of MEN1 (i.e. a mutant gene carrier)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

MEN1 - hyperparathyroidism / parathyroid adenoma

A

*95% of pts with MEN1
*younger age at diagnosis (in 20’s, compared to 50’s in sporadic hyperpara)
*multiple adenoma / 4 gland hyperplasia most commonly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

MEN1 - pituitary adenoma

A

*40% of pts with MEN1
*prolactinoma > acromegaly > other

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

MEN1 - pancreatic neuroendocrine tumors

A

*30-70% of pts with MEN1
*gastrinoma > non-functioning > insulinoma > other
*most common cause of death from this disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MEN2A - overview

A

*hallmark = medullary thyroid cancer
*100% of pts will get medullary thyroid cancer at some point
*monitor calcitonin levels, and treat with prophylactic thyroidectomy
*about 50% get pheochromocytoma
*about 30% get hyperparathyroidism (parathyroid adenoma)
*associated with RET mutation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MEN2A - associated gene

A

*RET proto-oncogene
*inheritance = autosomal dominant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

MEN2A - associated tumors

A

*medullary thyroid carcinoma
*plus, 2 P’s:
1. Parathyroid adenoma (hyperparathyroidism)
2. Pheochromocytoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MEN2A - additional manifestations

A

*2 possible variants:
1. cutaneous lichen amyloidosis
2. Hirschsprung’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

MEN2B - overview

A

*hallmark = medullary thyroid cancer
*early onset, aggressive MTC (often before age 10)
*mucosal neuromas & alacrima (inability to make tears) may be a tip-off
*also associated with Marfinoid habitus
*associated with RET mutation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

MEN2B - associated gene

A

*RET proto-oncogene
*inheritance = autosomal dominant

17
Q

MEN2B - associated tumors

A

*medullary thyroid carcinoma
*mucosal neuromas
*plus 1 P:
1. Pheochromocytoma

18
Q

MEN2B - additional manifestations

A

*Marfinoid habitus
*alacrima (inability to make tears)
*poor muscle tone, failure to thrive

19
Q

neuroendocrine tumors (NETs) - overview

A

*neuroendocrine tumors (NETs) is an umbrella term that encompasses all tumors that are derived from neuroendocrine cells
*can be categorized in a few ways:
1. functional vs. non-functional
2. well-differentiated (low-grade) vs. poorly differentiated (high grade)
3. pancreatic (pNET) vs. outside the pancreas (carcinoid tumor)
*other distinct tumors also fall under this umbrella, including pheochromocytoma and medullary thyroid carcinoma

20
Q

functional neuroendocrine tumors (NETs) - examples

A

note - “functional” = makes hormones
*carcinoid tumor/syndrome
*insulinoma
*gastrinoma (Zollinger-Ellison syndrome)
*VIPoma
*glucagonoma
*somatostatinoma

21
Q

carcinoid tumors - overview

A

*most commonly arise in digestive tract, with small intestine (midgut) being most common site; can also be bronchopulmonary
*arise from enterochromaffin-like (ECL) cells
*may secrete SEROTONIN and other vasoactive substances

22
Q

carcinoid syndrome - overview

A

*when **serotonin (5-HT) reaches systemic circulation (LIVER METASTASIS) and leads to systemic features from vasoactive substances&&
*most commonly occurs from carcinoid tumors in the midgut/small bowel
*does not occur with all carcinoid tumors

23
Q

carcinoid syndrome - clinical features

A

*EPISODIC FLUSHING, diarrhea, wheezing
*due to SEROTONIN, bradykinin, histamine, others

24
Q

carcinoid heart disease

A

*serotonin in systemic circulation reaches the right hear, and causes right-sided valve disease (fibrosis/stenosis, regurgitation, right heart failure)
*as serotonin passes through the lungs, it is metabolized to its inactive breakdown products (lungs contain monoamine oxidase); therefore, left side of heart is spared

25
Q

carcinoid syndrome - diagnosis

A

*24h urine 5-hydroxyindole acetic acid (5-HIAA) (looking for breakdown product of serotonin in the urine)
*imaging (octreoscan, Ga 68 PET-Dotatate)

26
Q

carcinoid syndrome - treatment

A

*surgery, if possible
*otherwise, somatostatin analogues (ex. octreotide), other chemotherapy

27
Q

neuroendocrine tumors (NETs) - somatostatin receptors

A

*NETs possess somatostatin receptors on the surface of their cells
*somatostatin (aka the “anti-hormone”) inhibits release of hormones: inhibits release of pituitary hormones, pancreatic hormones, and gastrin
*therefore, we can use somatostatin analogues (octreotide, lanreotide) to inhibit hormone release from these tumors

28
Q

insulinoma - overview

A

*tumor that arises from beta cells in the pancreas
*autonomously secrete insulin → hypoglycemia

29
Q

insulinoma - diagnosis

A

*to establish a diagnosis, patient should meet Whipple’s Triad:
1. documented hypoglycemia < 55
2. symptoms of hypoglycemia (diaphoresis, tremors, weakness, confusion, seizures)
3. symptoms resolve with consuming food to raise sugar
*we then try to measure labs during an episode of hypoglycemia

30
Q

insulinoma - hypoglycemia labs for dx

A

*in a patient with an insulinoma, during a hypoglycemic event, expect:
-insulin level: high (even normal is inappropriate because it should be low in a normal person)
-C peptide: high (even normal is inappropriate because it should be low in a normal person)

31
Q

gastrinoma - overview

A

*aka Zollinger-Ellison Syndrome (Z-E syndrome)
*tumor arises from G-cell (gastrin-producing cells) in the duodenum, gastric antrum, or pancreas
*autonomous gastrin secretion → increased acidity in the stomach → ULCERS

32
Q

VIPoma - overview

A

*VIP = vasoactive intestinal peptide
*VIPoma aka Pancreatic Cholera
*classic triad: watery diarrhea, hypokalemia (mostly from diarrhea), achlorhydria (lack of hydrochloric acid; VIP inhibits acid secretion) / increased gastric pH
*these patients can also have flushing (vasoactive)

33
Q

glucagonoma - overview

A

*arises from alpha cells in pancreas
*glucagon functions as the opposite of insulin: inhibits glucose uptake into cells
*results in diabetes, weight loss, and a characteristic rash
*characteristic rash = Necrolytic Migratory Erythema: red blistering rash, usually on lower extremities

34
Q

somatostatinoma - overview

A

*arises from the D-cells (delta cells)
*somatostatin = anti-hormone
*main signs/symptoms:
-decreased insulin production → diabetes
-decreased pancreatic exocrine function → steatorrhea / diarrhea
-decreased gallbladder contractility → cholelithiasis

35
Q

autoimmune polyglandular syndromes - overview

A

*most autoimmune endocrine disorders occur in isolation; however, there are situations when patients will develop multiple autoimmune endocrine disorders +/- other autoimmune disorders
*2 distinct syndromes exist: APS-I and APS-II

36
Q

autoimmune polyglandular syndromes: APS-I

A

*associated with mutations in the AIRE gene (autoimmune regulator gene: responsible for presenting various antigens in the thymus to help week out the T cells that target self)
*autosomal recessive
*presents in INFANCY
*associations:
-mucocutaneous candidiasis
-autoimmune hypoparathyroidism
-Addison’s disease

-ectodermal dysplasia (pitted nails, poor enamel)
-primary ovarian failure
-pernicious anemia
-T1DM
-hypothyroidism

37
Q

autoimmune polyglandular syndromes: APS-II

A

*polygenic
*presents age 20-60 years
*2 or more of the following:
-Addison’s disease
-autoimmune thyroid disease (Grave’s or Hashimoto’s)
-T1DM
-celiac disease
-primary hypogonadism
-myasthenia gravis

38
Q

McCune-Albright Syndrome

A

*activating mutation in GNAS gene → constitutively active G-protein coupled receptor → cAMP signaling → hormone hypersecretion
*classic triad: fibrous dysplasia of bone (results in fractures), Cafe-au-lait spots, precocious (early) puberty
*also, hyperthyroidism, growth hormone excess, hypercortisolism

note - the Cafe-au-lait spots are “Coast of Maine” presentation